| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano [F. C., M. B., R. V., G. F.]; Department of Oncology and Neurosciences, University of Chieti, 66100 Chieti [E. D. C., P. M.]; and National Tumor Institute, 20133 Milan [M. P. C.], Italy
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
) and third-level chemokines (inducible protein 10 and monokine induced by IFN-); (b) systemic activation of leukocyte subsets capable of producing proinflammatory cytokines, CTLs, and antitumor antibodies; and (c) destruction of tumor vessels by polymorphonuclear cells. The markedly higher efficacy of systemic rIL-12 seems to rest on its ability to recruit these systemic reactions more quickly and efficiently than local rIL-12. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
To gain insight into a few of these issues, we compared the effects of local and systemic rIL-12 administration in mice harboring an aggressive, metastasizing, and moderately differentiated mammary adenocarcinoma (TSA; Ref. 21 ). It was found that rIL-12 therapeutic activity ranged from very high to moderate according to the administration route alone. The immune reactions elicited via the two routes seem to be the same. The variation in the efficacy of rIL-12 seems to be determined by the differences in action kinetics and intensity.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
(PharMingen, San Diego, CA) and then dissolved in Ultraspect (Biotecx Laboratories, Inc., Houston, TX) for total mRNA extraction.
Mice.
Female 7-week-old BALB/c mice (Charles River Laboratories) were treated in accordance with the European Community guidelines. When required, mice were selectively immunodepressed by in vivo treatment with antibodies specific for leukocyte subpopulations, as reported previously in detail (10)
.
Mouse rIL-12.
Mice received two courses of five daily injections (with a 2-day interval) of mouse rIL-12 (Dr. Michael Brunda, Hoffmann-La Roche, Nutley, NJ) diluted in HBSS supplemented with 100 µg/ml MSA (Sigma). rIL-12 (100 ng/day) was injected either locally s.c. in the tumor area or systemically i.p. (10)
. Control mice received HBSS with MSA only (MSA controls).
In Vivo Evaluation of Solid Tumors.
At day 0, mice were challenged s.c. in the left flank with 0.2 ml of a single cell suspension containing 4 x 104 TSA cells. This is about the minimal 100% tumor-inducing dose of TSA cells in BALB/c mice (21)
. The cages were then coded, and tumor incidence and growth were evaluated as reported previously (10)
.
Spontaneous Lung Metastasis.
A few mice bearing s.c. TSA tumor masses with a mean diameter of 8–10 mm were anesthetized with ketamine hydrochloride (Ketavet; Farmaceutici Gellini, Aprilia, Italy), and the tumor was removed through a 6-mm-long skin cut and careful dissection. The few mice that eventually displayed local tumor relapse were excluded from the experiment. Spontaneous metastases grew in the lungs of mice that were successfully treated surgically. These mice died about 50 days after surgery from respiratory failure due to outgrowth of the metastases.
CTL Activity.
This was evaluated after three and eight injections of rIL-12, i.e., 10 and 17 days after tumor challenge. The CTL activity of SPCs that were restimulated for 6 days with mitomycin C (Sigma) in the presence of 20 units/ml rIL-2 (Eurocetus, Milan, Italy) against [3H]thymidine-labeled target cells was determined as described previously (21)
, and the values were expressed as the percentage of lysis and lytic unit/1 x 107 effector cells calculated according to the equation of Pross (25)
.
Cytokine Production.
Supernatants from SPCs that were restimulated in vitro with soluble anti-CD3 and soluble anti-CD28 (2 µg/ml each; PharMingen) were collected after an 18-h culture and tested for IL-4 and IFN- titer using ELISA kits (PharMingen).
Morphological Analysis.
For histological evaluation, tissue samples from groups of five mice killed 10 or 17 days after the TSA challenge were fixed, embedded in paraffin, sectioned at 4 µm, and stained with H&E or Giemsa. For immunohistochemistry, acetone-fixed cryostat sections were incubated for 30 min with the following antibodies: anti-MAC-1, anti-MAC-3, anti-I-A/I-E, and anti-IL-6 (PharMingen); anti-PMNs [RB6-8C5 hybridoma; provided by Dr. R. L. Coffman (DNAX, Inc., Palo Alto, CA)]; anti-L3T4 (CD4) and anti-Lyt-2 (CD8; Sera-Lab, Sussex, United Kingdom); anti-Asialo GM1 (Wako Chemicals Gm&H, Dusseldorf, Germany); anti-IL-1ß (Genzyme, Cambridge, MA); anti-TNF-
(Immuno Kontact, Frankfurt, Germany); anti-IFN- [provided by Dr. S. Landolfo (University of Turin, Turin, Italy)]; anti-CD31 (MEC-13.3) and anti-ELAM-1 (E-selectin; both provided by Dr. A. Vecchi (Istituto M. Negri, Milan, Italy)]; anti-ICAM-1 (CD54) and anti-VCAM-1 (PharMingen); and anti-iNOS (Transduction Laboratories, Lexington, KY). After washing, they were overlaid with biotinylated goat antirat, antihamster, and antirabbit and horse and goat immunoglobulin (Vector Laboratories, Burlingame, CA) for 30 min. Unbound immunoglobulin was removed by washing, and the slides were incubated with avidin-biotin complex/alkaline phosphatase (DAKO, Glostrup, Denmark). Quantitative studies of the immunohistochemically stained sections were performed by three pathologists in a blind fashion on three or more samples from distinct mice by evaluating 10 randomly chosen fields in each sample. Individual cells were counted under a x400 microscopic field (x40 objective and x10 ocular lens; 0.180 mm2/field). The expression of cytokines and adhesion molecules was defined as absent (-) or scarcely (±), moderately (+), or frequently (++) present on the cryostat sections tested with the corresponding antibody.
RNA-Cytokine Production at the Tumor Site.
Total RNA was prepared from fresh tumor masses from three mice bearing 10- or 17-day-old tumors that were treated or not treated with rIL-12. Total RNA was extracted using Ultraspect (Biotecx Laboratories, Inc.). RNA (2 µg) was reverse transcribed by using Moloney murine leukemia virus reverse transcriptase (200 units) in 50 ml of reaction mixture with oligodeoxythymidylic acid and deoxynucleotide triphosphate (all from Life Technologies, Inc., Paisley, United Kingdom). Each cDNA (5 ml) was diluted in a 50-ml reaction mixture (GeneAmp Kit; Perkin-Elmer Corp., Norwalk, CT) and amplified by 30 PCR cycles to identify the presence of murine glyceraldehyde-3-phosphate dehydrogenase, IL-1ß, IL-4, IL-6, IL-10, IFN-, TGF-ß1, TNF-, and iNOS gene sequences by using specific primer pairs (Clontech, Palo Alto, CA). PCR primers were used for murine IFN IP-10 (5'-GCGTTAACCTCCCCATCAGCACCATGAAC and 3'-CCGCTCGAGGTGGCTTCTCTCCAGTTAAGGA), MIG (5'-TCCGCTGTTCTTTTCCTTTTGG and 3'-TTGAACGACGACGACTTTGGGG), ICAM-1 (5'-GACTCTGTGTCAGCCACTGCCTT and 3'-CTCCTCCTGAGCCTTCTGTAACT), VCAM (5'-GCTGCGAGTCACCCATTGTTCT and 3'-CCAGATGGTCGAGGACT CTAA), and ELAM (5'-TACTACAATGCCTCCAGTGAG and 3'-ACATCTCTCGTCATTCCACAT). The bands were defined as almost absent (±), faint (+), intense (++), and very marked (+++).
Immune Sera.
Three pools of sera from groups of five mice each were collected 10 and 17 days after tumor challenge. Normal sera were three pools from five age-matched, untreated female mice. The total amount of IgM, IgA, IgG1, IgG2a, IgG2b, and IgG3 was evaluated by radial immunodiffusion using the mouse immunoglobulin NL RID kits (The Binding Site, Ltd., Birmingham, United Kingdom). The specific TSA binding potential of the sera was evaluated by flow cytometry after indirect immunofluorescence, as described previously in detail (21)
.
Statistical Analysis.
All in vivo experiments were performed two or three times with groups of five to eight mice, and the results were cumulated as they gave homogeneous results. The significance of differences in tumor takes was determined by Pearson’s 
2 test.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
.
|
. CD4+ cells were certainly not involved in the rejection provoked by i.p. rIL-12. The major roles were played by CD8+ cells and PMNs and, to a lesser extent, by NK cells.
|
. Vessel alteration and leukocyte infiltration were evident. At day 17, after eight i.p. rIL-12 administrations, the necrotic areas were large and numerous, and the tumor mass was often completely destroyed. Intratumoral and peritumoral vessels were severely damaged and frequently obstructed by thrombi. These features were much less pronounced after three or eight local administrations.
|
. In mice that received local rIL-12, only the number of CD8+ lymphocytes and NK cells was significantly higher. At day 17, tumor-infiltrating CD8+ and CD4+ lymphocytes were significantly more numerous after both treatments than they were in the controls. However, whereas in mice receiving rIL-12 i.p., the number of macrophages was also significantly higher, in those receiving local rIL-12, the number of NK cells was significantly higher. These increments in infiltrating leukocytes were paralleled by an increased expression of VCAM-1 by tumor vessels. The expression of IL-1ß, TNF-, IFN-, and iNOS was more marked in both i.p. and s.c. treated mice than in MSA controls. TNF- and IFN- were more strongly expressed in the i.p. treated group.
|
, TNF-, IL-1ß, ICAM-1, VCAM-1, ELAM-1 (Table 1)
, and IL-4 (data not shown) was evident in the tumor growth area of mice that had received three local or i.p. administrations of rIL-12 compared to the controls. As suggested by the histological data, most of the tumor is necrotic by day 17. At this time, the mRNA for IL-6 and IL-10 becomes evident (data not shown), whereas that for IFN-, IP-10, MIG (Table 1)
, and TGF-ß1 (data not shown) decreases.
CTL Reactivity against TSA Cells.
The rIL-12-provoked cytotoxicity against TSA cells was evaluated in SPCs that were restimulated in vitro with TSA cells in the presence of 20 units of IL-2 and assessed for CTL activity. SPCs obtained at day 10 after three local or i.p. rIL-12 administrations displayed a significantly higher TSA-specific CTL activity than MSA controls (Table 2)
. Moreover, the CTL activity of mice receiving rIL-12 i.p. was significantly higher than it was in those treated locally. No increase was found in normal mice receiving rIL-12 either locally or i.p (Table 2)
.
|
. A slight increase was also evident in normal mice that received rIL-12 either locally or i.p. No increase was found against antigenically unrelated F1F target cells at any time (data not shown).
Cytokine Release.
SPCs from five mice were pooled and restimulated in vitro for 18 h with soluble anti-CD3 and anti-CD28 monoclonal antibody to evaluate their ability to produce IFN- and IL-4. IFN- production decreased from about 15 ng/ml before tumor challenge to 11.6 (Fig. 4
, top) and 8.3 (Fig. 4
, bottom) ng/ml 10 and 17 days after tumor challenge, respectively. Both s.c. and i.p. rIL-12 administration to tumor-bearing mice maintained IFN- production at normal levels. In normal mice, rIL-12 administration enhanced IFN- production.
|
Antibodies to TSA.
After three rIL-12 administrations (day 10), only tumor-bearing mice receiving rIL-12 i.p. displayed a significant increase in anti-TSA antibodies, which was mostly due to higher levels of IgG1 and IgG3 (Table 3)
. The amount of IgM and IgA did not change, whereas IgG2a and IgG2b remained undetectable. No significant isotype variation (data not shown) or increase in anti-TSA antibodies (Table 3)
was found after local rIL-12. Normal mice treated with local or i.p. rIL-12 or MSA only did not display isotype variations (data not shown) or anti-TSA antibodies (Table 3)
.
|
, which was associated with a generalized increase in the IgG titer (data not shown). However, the increase was more evident in mice receiving rIL-12 s.c. and was associated with an increase in IgA concentration to 1250 mg/liter from 1100 mg/liter in tumor-bearing mice treated or not treated with rIL-12 i.p. The increase in anti-TSA antibody was also found in normal mice receiving i.p. rIL-12 (Table 3)
. An increase in antibodies binding the antigenically unrelated F1F cells paralleled the increases of anti-TSA antibodies. However, these increases were lower and were either barely significant or not significant (data not shown).
Curative Potential of rIL-12 against Spontaneous Metastases.
Multiple spontaneous lung metastases become evident during the growth of s.c. TSA tumors (Fig. 5B)
. To evaluate whether the anatomical site of the tumor also influences the therapeutic potential of rIL-12, mice from which s.c. TSA tumors that were 10 mm in mean diameter had been surgically removed (Fig. 5A)
were left to recover from the anesthesia and surgical shock for 2 weeks and then received three i.p. 5-day/week courses of rIL-12 or MSA only. MSA controls died within 40 days after surgery due to respiratory failure associated with the overgrowth of metastases. In contrast, the survival of rIL-12-treated mice was significantly enhanced (Fig. 5C)
. At the end of the experiment (day 100 after surgery), 50% were still alive. Whereas PMNs seem to play no role, the cure was abrogated by the removal of CD8+ lymphocytes and was significantly weakened by the removal of NK cells (Fig. 2)
.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
and IL-4 secretion, and the appearance of serum antibodies, in fact, are all earlier and more effective. In this case, NK cells are also an additional component of the antitumor reaction. This greater speed and intensity is associated with the more effective curing of large s.c. tumors. The same dose of rIL-12 administered i.p. or locally has a different effect. Whereas i.p. rIL-12 rapidly diffuses in the body fluids, reaching low concentrations and promptly triggering an antitumor reaction, the local persistence of high doses of rIL-12 may favor the induction of immunosuppressive effects (17)
.
In these studies, the therapeutic efficacy of local and systemic rIL-12 was tested against a large, highly invasive, 7-day-old TSA tumor. The tumor mass formed at this time is well vascularized by self-induced neoformed vessels (23)
. Investigation of the events associated with the partial or total destruction of these relatively large and actively proliferating tumor masses provides an indication of the antitumor mechanisms of rIL-12 (Fig. 6)
. However, the activation of a given immune activity suggests that it plays a role. It also serves to illustrate the distinctive features of the reaction but clearly does not directly define the weight of its role in tumor inhibition.
|
and TNF- is one of the most important events triggered by rIL-12 in these cells (26)
. These cytokines synergize during monocyte and macrophage activation. Macrophages are usually associated with TSA (24)
as well as many mouse and human tumors (27)
. After their activation by IFN- and TNF-, they become a source of tertiary cytokines and mediators secreted in the tumor environment. rIL-12 administration, in fact, was followed by local expression of the mRNA of IL-1ß, IFN-, TNF-, IP-10, MIG, and iNOS in the tumor microenvironment. Immunohistochemically, IL-1ß, IFN-, TNF-, and iNOS expression was localized in cells that were morphologically identifiable as macrophages.
Besides their action on immune cells, secondary cytokines seem to affect TSA cells directly. rIL-12-elicited IFN- induces overexpression of MHC glycoproteins on the TSA cell surface (28)
. It also induces TSA cells to generate antiangiogenic activity, as observed with other tumors (7
, 20
, 29)
. TSA cells cultured in vitro express a slight amount of IP-10 mRNA but do not express mRNA for MIG. After 48 h of incubation with rIFN-, TSA cells displayed both MIG mRNA and an increased expression of IP-10 mRNA (data not shown). This IFN--dependent induction of antiangiogenic activity can explain the necrotic areas observed during the delayed progression of TSA cells engineered to produce IFN- (24
, 28)
. This modulation of antiangiogenic factors fits in well with the data showing that their expression by normal and diseased tissues is associated with tissue necrosis and vascular damage (30)
.
IFN- and TNF-, along with third-level antiangiogenic chemokines and factors, are able to preferentially activate neoformed endothelium and induce the expression of adhesion molecules, as we have observed in peritumoral and intratumoral vessels of rIL-12-treated mice (9
, 10)
. Third-level chemokines (IP-10 and MIG; Ref. 6
and 31
) and iNOS (32
, 33)
as well as secondary IFN- and TNF- (34)
may contribute to the inhibition of neoangiogenesis and the damaging of neoformed vessels. Because they are expressed at high levels in tumors from rIL-12-treated mice, all of these factors may be directly responsible for the ischemic necrotic process that characterizes the rejection of established TSA tumors. Indeed, in many tumor models, the inhibition of tumor angiogenesis is an important part of the systemic antitumor effect produced by rIL-12 (9
, 10
, 35)
.
Endothelial adhesion molecules, and VCAM-1 in particular, are directly involved in tumor leukocyte recruitment (36 , 37) . Massive recruitment of CD8+ lymphocytes was clearly shown by morphological examination of tumors from mice treated three or eight times with rIL-12 and may depend on IP-10 and MIG selective chemotaxis for CD8+ cells (38) . Their key role in the antitumor reaction elicited by rIL-12 is endorsed by the results obtained in many other systems (1 , 10 , 16 , 17) as well as by the present findings in selectively immunodepleted mice. The removal of CD8 lymphocytes almost completely abolished the ability of i.p. rIL-12 to cure s.c. tumors and lung metastases. The less important role of CD8+ lymphocytes when rIL-12 is injected s.c. may be no more than apparent due to the poor therapeutic efficacy of s.c. rIL-12. Furthermore, systemic rIL-12 results in a more rapid induction of specific anti-TSA CTLs in the spleen of tumor-bearing mice. At day 17, there seems to be no difference in the CTL response induced by systemic or local IL-12. At this late time, the differences in the intensity of CTL activity are no longer evident.
PMNs seem to have no role in the inhibition of lung metastases, whereas they are of crucial importance against s.c. tumors, because their selective depletion abolishes the effect of both s.c. and i.p. rIL-12. Differences in the accessibility of the tumor microenvironment, blood supply, and resident lymphoid cells, especially macrophages, between the lung and the s.c. tissue may account for their distinct weight (39) . The number of tumor-infiltrating PMNs was significantly enhanced after three i.p. administrations of rIL-12. This rapid influx of PMNs endowed with a high destructive potential is probably involved in the vascular damage (40) and subsequent extensive ischemic/hemorrhagic necrosis observed after three and eight i.p. administrations. Their early recruitment may be supported by the marked expression of ELAM-1 by the tumor vessels, because this was almost absent in locally treated mice and the controls.
As has been shown with many tumors (41)
, SPCs released fewer cytokines as the TSA tumor mass increased. Both s.c. and i.p. rIL-12 restored the IFN- production of SPCs from tumor-bearing mice to normal levels and enhanced that of normal mice, as observed by Nastala et al. (2)
and Fujiwara et al. (19
, 20)
. Three s.c. or i.p. administrations inhibited the production of IL-4, a typical class II lymphokine, in both normal and (to a lesser extent) tumor-bearing mice, whereas eight administrations increased it.
The role of antitumor antibodies is still unclear (7 , 24 , 42) . Even so, their production is stimulated by both local and systemic rIL-12. Anti-TSA antibodies appeared after only three systemic administrations, and their level was unchanged after eight administrations, whereas their production was not induced by three local administrations and only became evident and very marked after eight administrations. The kinetics of this production was correlated with the production of IL-4 by SPCs.
In conclusion, our data indicate that rIL-12 is effective against a large and highly vascularized tumor. Its systemic administration is more powerful than local administration. Tumor destruction is dependent on a prompt antitumor response that must result from the cooperation of several subsets of reactive cells. Three events seem to be of major importance: (a) the destruction of tumor vessels by PMNs; (b) the indirect inhibition of angiogenesis by secondary IFN- and TNF- and third-level chemokines (IP-10 and MIG); and (c) the activation of leukocyte subsets capable of producing proinflammatory cytokines, CTLs, and antitumor antibodies.
After eight rIL-12 administrations (day 17 after tumor challenge), when tumor rejection comes to an end, the local immune response probably starts to wane, as suggested by the appearance of mRNA for IL-6 and IL-10 and a decrease in the production of that for IFN-, IP-10, MIG, and vascular endothelial growth factor ß (Table 2)
.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by the Italian Association for Cancer Research and by grants from Istituto Superiore di Sanitá, Special Project on Tumor Therapy, and Consiglio Nazionale delle Ricerche, Target Projects Applicazioni Cliniche della Ricerca Oncologica and Biotechnology. 
2 To whom requests for reprints should be addressed, at the Department of Clinical and Biological Sciences, Ospedale San Luigi Gonzaga, 10043 Orbassano, Italy. Phone: 39-0119-038-638; Fax: 39-0119-038-639; E-mail: forni{at}pasteur.sluigi.unito.it
3 The abbreviations used are: IL, interleukin; MSA, mouse serum albumin, PMN, polymorphonuclear leukocyte; r, recombinant; SPC, spleen cell; TGF-ß1, transforming growth factor ß1; iNOS, inducible NO synthetase; NK, natural killer; VCAM, vascular cell adhesion molecule; ICAM-1, intracellular adhesion molecule 1; ELAM, endothelial leukocyte adhesion molecule; IP-10, inducible protein 10; MIG, monokine induced by IFN-.
Received 7/27/98. Accepted 11/10/98.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
production. J. Immunol., 153: 1697-1706, 1994.[Abstract]
production by antitumor T cells. Int. Immunol., 7: 1135-1145, 1995.-interferon gene. Int. J. Cancer, 55: 320-329, 1993.[Medline]
affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity, 9: 25-34, 1998.[Medline]
, and IP-10, the interferon--inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative diseases. Blood, 90: 4099-4110, 1997.Vß3 in the disruption of the tumor vasculature induced by TNF and IFN-. Nat. Med., 4: 408-414, 1998.[Medline]
This article has been cited by other articles:
|
|
 |
|
  M. O. Kilinc, K. S. Aulakh, R. E. Nair, S. A. Jones, P. Alard, M. M. Kosiewicz, and N. K. Egilmez Reversing Tumor Immune Suppression with Intratumoral IL-12: Activation of Tumor-Associated T Effector/Memory Cells, Induction of T Suppressor Apoptosis, and Infiltration of CD8+ T Effectors J. Immunol., November 15, 2006; 177(10): 6962 - 6973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Comes, O. Rosso, A. M. Orengo, E. Di Carlo, C. Sorrentino, R. Meazza, T. Piazza, B. Valzasina, P. Nanni, M. P. Colombo, et al. CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine J. Immunol., February 1, 2006; 176(3): 1750 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Lopez, S. K. Adris, A. I. Bravo, Y. Chernajovsky, and O. L. Podhajcer IL-12 and IL-10 Expression Synergize to Induce the Immune-Mediated Eradication of Established Colon and Mammary Tumors and Lung Metastasis J. Immunol., November 1, 2005; 175(9): 5885 - 5894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Arbel-Goren, Y. Levy, D. Ronen, and Y. Zick Cyclin-dependent Kinase Inhibitors and JNK Act as Molecular Switches, Regulating the Choice between Growth Arrest and Apoptosis Induced by Galectin-8 J. Biol. Chem., May 13, 2005; 280(19): 19105 - 19114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Spadaro, E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W.-Z. Wei, P. Musiani, P.-L. Lollini, et al. Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity Clin. Cancer Res., March 1, 2005; 11(5): 1941 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Croce, R. Meazza, A. M. Orengo, L. Radic', B. De Giovanni, C. Gambini, B. Carlini, V. Pistoia, L. Mortara, R. S. Accolla, et al. Sequential Immunogene Therapy with Interleukin-12- and Interleukin-15-Engineered Neuroblastoma Cells Cures Metastatic Disease in Syngeneic Mice Clin. Cancer Res., January 15, 2005; 11(2): 735 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harada, M. Shimada, S. Okano, T. Suehiro, Y. Soejima, Y. Tomita, and Y. Maehara IL-12 Gene Therapy Is an Effective Therapeutic Strategy for Hepatocellular Carcinoma in Immunosuppressed Mice J. Immunol., December 1, 2004; 173(11): 6635 - 6644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mitsuhashi, J. Liu, S. Cao, X. Shi, and X. Ma Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas J. Leukoc. Biol., August 1, 2004; 76(2): 322 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, Z. Xiang, and X. Ma Role of IFN Regulatory Factor-1 and IL-12 in Immunological Resistance to Pathogenesis of N-Methyl-N-Nitrosourea-Induced T Lymphoma J. Immunol., July 15, 2004; 173(2): 1184 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guiducci, E. Di Carlo, M. Parenza, M. Hitt, M. Giovarelli, P. Musiani, and M. P. Colombo Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor J. Immunol., April 1, 2004; 172(7): 4026 - 4036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Di Carlo, A. Comes, A. M. Orengo, O. Rosso, R. Meazza, P. Musiani, M. P. Colombo, and S. Ferrini IL-21 Induces Tumor Rejection by Specific CTL and IFN-{gamma}-Dependent CXC Chemokines in Syngeneic Mice J. Immunol., February 1, 2004; 172(3): 1540 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Satoh, T. Saika, S. Ebara, N. Kusaka, T. L. Timme, G. Yang, J. Wang, V. Mouraviev, G. Cao, E. M. A. Fattah, et al. Macrophages Transduced with an Adenoviral Vector Expressing Interleukin 12 Suppress Tumor Growth and Metastasis in a Preclinical Metastatic Prostate Cancer Model Cancer Res., November 15, 2003; 63(22): 7853 - 7860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Cuadrado, M. d. C. Moreno Koch, C. F. Perez, L. M. Castejon Castan, C. P. Villalobos, M. J. Gonzalez Mateos, and C. L. Olmos Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound Clin. Cancer Res., November 15, 2003; 9(15): 5776 - 5785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mitola, M. Strasly, M. Prato, P. Ghia, and F. Bussolino IL-12 Regulates an Endothelial Cell-Lymphocyte Network: Effect on Metalloproteinase-9 Production J. Immunol., October 1, 2003; 171(7): 3725 - 3733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Chhokar and A. L. Tucker Angiogenesis: Basic Mechanisms and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280. [Abstract] [PDF]
|
|
|
|
|
|
A. M. Orengo, E. Di Carlo, A. Comes, M. Fabbi, T. Piazza, M. Cilli, P. Musiani, and S. Ferrini Tumor Cells Engineered with IL-12 and IL-15 Genes Induce Protective Antibody Responses in Nude Mice J. Immunol., July 15, 2003; 171(2): 569 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Roca, L. Primo, D. Valdembri, A. Cividalli, P. Declerck, P. Carmeliet, P. Gabriele, and F. Bussolino Hyperthermia Inhibits Angiogenesis by a Plasminogen Activator Inhibitor 1-dependent Mechanism Cancer Res., April 1, 2003; 63(7): 1500 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nanni, G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, F. Cavallo, S. M. Pupa, I. Rossi, M. P. Colombo, C. Ricci, et al. Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice J. Exp. Med., October 29, 2001; 194(9): 1195 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cifaldi, E. Quaglino, E. Di Carlo, P. Musiani, M. Spadaro, P. L. Lollini, S. Wolf, K. Boggio, G. Forni, and F. Cavallo A Light, Nontoxic Interleukin 12 Protocol Inhibits HER-2/neu Mammary Carcinogenesis in BALB/c Transgenic Mice with Established Hyperplasia Cancer Res., April 1, 2001; 61(7): 2809 - 2812. [Abstract] [Full Text]
|
|
|
|
|
|
F. Cavallo, E. Quaglino, L. Cifaldi, E. Di Carlo, A. André, P. Bernabei, P. Musiani, G. Forni, and R. A. Calogero Interleukin 12-activated Lymphocytes Influence Tumor Genetic Programs Cancer Res., April 1, 2001; 61(8): 3518 - 3523. [Abstract] [Full Text]
|
|
|
|
|
|
J.-W. Park, M. E. Gruys, K. McCormick, J.-K. Lee, J. Subleski, J. M. Wigginton, R. G. Fenton, J.-M. Wang, and R. H. Wiltrout Primary Hepatocytes from Mice Treated with IL-2/IL-12 Produce T Cell Chemoattractant Activity that Is Dependent on Monokine Induced by IFN-{{gamma}} (Mig) and Chemokine Responsive to {{gamma}}-2 (Crg-2) J. Immunol., March 15, 2001; 166(6): 3763 - 3770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Strasly, F. Cavallo, M. Geuna, S. Mitola, M. P. Colombo, G. Forni, and F. Bussolino IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk J. Immunol., March 15, 2001; 166(6): 3890 - 3899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-i. Yamashita, M. Shimada, H. Hasegawa, R. Minagawa, T. Rikimaru, T. Hamatsu, S. Tanaka, K. Shirabe, J.-i. Miyazaki, and K. Sugimachi Electroporation-mediated Interleukin-12 Gene Therapy for Hepatocellular Carcinoma in the Mice Model Cancer Res., February 1, 2001; 61(3): 1005 - 1012. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Di Carlo, G. Forni, P. Lollini, M. P. Colombo, A. Modesti, and P. Musiani The intriguing role of polymorphonuclear neutrophils in antitumor reactions Blood, January 15, 2001; 97(2): 339 - 345. [Full Text] [PDF]
|
|
|
|
 |
|
 H.M. Pinedo, T.D. de Gruijl, E. van der Wall, and J. Buter Biological Concepts of Prolonged Neoadjuvant Treatment plus GM-CSF in Locally Advanced Tumors Oncologist, December 1, 2000; 5(6): 497 - 500. [Abstract] [Full Text]
|
|
|
|
|
|
K. J. Andrews, A. Ribas, L. H. Butterfield, C. M. Vollmer, F. C. Eilber, V. B. Dissette, S. D. Nelson, P. Shintaku, S. Mekhoubad, T. Nakayama, et al. Adenovirus-Interleukin-12-mediated Tumor Regression in a Murine Hepatocellular Carcinoma Model Is Not Dependent on CD1-restricted Natural Killer T Cells Cancer Res., November 1, 2000; 60(22): 6457 - 6464. [Abstract] [Full Text]
|
|
|
|
|
|
S. Rovero, A. Amici, E. D. Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P.-L. Lollini, et al. DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice J. Immunol., November 1, 2000; 165(9): 5133 - 5142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Di Carlo, A. Comes, S. Basso, A. De Ambrosis, R. Meazza, P. Musiani, K. Moelling, A. Albini, and S. Ferrini The Combined Action of IL-15 and IL-12 Gene Transfer Can Induce Tumor Cell Rejection Without T and NK Cell Involvement J. Immunol., September 15, 2000; 165(6): 3111 - 3118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Egilmez, Y. S. Jong, M. S. Sabel, J. S. Jacob, E. Mathiowitz, and R. B. Bankert In Situ Tumor Vaccination with Interleukin-12-encapsulated Biodegradable Microspheres: Induction of Tumor Regression and Potent Antitumor Immunity Cancer Res., July 1, 2000; 60(14): 3832 - 3837. [Abstract] [Full Text]
|
|
|
|
|
|
G. Forni, P. L. Lollini, P. Musiani, and M. P. Colombo Immunoprevention of Cancer: Is the Time Ripe? Cancer Res., May 1, 2000; 60(10): 2571 - 2575. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Gollob, J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-{{gamma}} Induction Is Associated with Clinical Response Clin. Cancer Res., May 1, 2000; 6(5): 1678 - 1692. [Abstract] [Full Text]
|
|
|
|
|
|
K. Boggio, E. Di Carlo, S. Rovero, F. Cavallo, E. Quaglino, P. L. Lollini, P. Nanni, G. Nicoletti, S. Wolf, P. Musiani, et al. Ability of Systemic Interleukin-12 to Hamper Progressive Stages of Mammary Carcinogenesis in HER2/neu Transgenic Mice Cancer Res., January 1, 2000; 60(2): 359 - 364. [Abstract] [Full Text]
|
|
|
|
|
|
M. Stolina, S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. W. Miller, J. Portanova, et al. Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis J. Immunol., January 1, 2000; 164(1): 361 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Schmidt and M. F. Mescher Adjuvant Effect of IL-12: Conversion of Peptide Antigen Administration from Tolerizing to Immunizing for CD8+ T Cells In Vivo J. Immunol., September 1, 1999; 163(5): 2561 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shoenfeld and P. Fishman Gamma-globulin inhibits tumor spread in mice Int. Immunol., August 1, 1999; 11(8): 1247 - 1252. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
